{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:16:37Z","timestamp":1793859397289,"version":"4.6.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s00415-022-10973-8","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T09:03:02Z","timestamp":1643101382000},"page":"3588-3596","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The importance of tissue-based assay in the diagnosis of autoimmune encephalitis"],"prefix":"10.1007","volume":"269","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1917-9349","authenticated-orcid":false,"given":"Avi","family":"Gadoth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahel","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Paran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orna","family":"Aizenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifat","family":"Alcalay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,25]]},"reference":[{"issue":"5","key":"10973_CR1","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1212\/WNL.50.5.1483","volume":"50","author":"F Heidenreich","year":"1998","unstructured":"Heidenreich F, Vincent A (1998) Antibodies to ion-channel proteins in thymoma with myasthenia, neuromyotonia, and peripheral neuropathy. Neurology 50(5):1483\u20131485","journal-title":"Neurology"},{"issue":"3","key":"10973_CR2","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1212\/WNL.54.3.771","volume":"54","author":"PA Barber","year":"2000","unstructured":"Barber PA, Anderson NE, Vincent A (2000) Morvan\u2019s syndrome associated with voltage-gated K+ channel antibodies. Neurology 54(3):771\u2013772","journal-title":"Neurology"},{"issue":"5","key":"10973_CR3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/(SICI)1097-4598(200005)23:5<655::AID-MUS1>3.0.CO;2-E","volume":"23","author":"A Vincent","year":"2000","unstructured":"Vincent A (2000) Understanding neuromyotonia. Muscle Nerve 23(5):655\u2013657","journal-title":"Muscle Nerve"},{"key":"10973_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/ana.1097","volume":"50","author":"C Buckley","year":"2001","unstructured":"Buckley C, Oger J, Clover L et al (2001) Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 50:73\u201378","journal-title":"Ann Neurol"},{"key":"10973_CR5","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1093\/brain\/awh077","volume":"127","author":"A Vincent","year":"2004","unstructured":"Vincent A, Buckley C, Schott JM et al (2004) Potassium channel antibodyassociated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 127:701\u2013712","journal-title":"Brain"},{"key":"10973_CR6","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1212\/01.WNL.0000122648.19196.02","volume":"62","author":"MJ Thieben","year":"2004","unstructured":"Thieben MJ, Lennon VA, Boeve BF et al (2004) Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 62:1177\u20131182","journal-title":"Neurology"},{"key":"10973_CR7","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1212\/01.wnl.0000312275.04260.a0","volume":"70","author":"KM Tan","year":"2008","unstructured":"Tan KM, Lennon VA, Klein CJ, Boeve BF, Pittock SJ (2008) Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 70:1883\u20131890","journal-title":"Neurology"},{"issue":"1","key":"10973_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/ana.21050","volume":"61","author":"J Dalmau","year":"2007","unstructured":"Dalmau J, T\u00fcz\u00fcn E, Hai-yan WU et al (2007) Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 61(1):25\u201336","journal-title":"Ann Neurol"},{"issue":"11","key":"10973_CR9","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1212\/WNL.0000000000004356","volume":"89","author":"AS L\u00f3pez-Chiriboga","year":"2017","unstructured":"L\u00f3pez-Chiriboga AS, Clardy SL (2017) Emerging subspecialties in neurology: autoimmune neurology. Neurology 89(11):e129\u2013e133","journal-title":"Neurology"},{"issue":"2","key":"10973_CR10","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/ana.24872","volume":"81","author":"A Gadoth","year":"2017","unstructured":"Gadoth A, Kryzer TJ, Fryer J et al (2017) Microtubule-associated protein 1B: novel paraneoplastic biomarker. Ann Neurol 81(2):266\u2013277","journal-title":"Ann Neurol"},{"key":"10973_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","volume":"15","author":"F Graus","year":"2016","unstructured":"Graus F, Titulaer MJ, Balu R et al (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15:391\u2013404","journal-title":"Lancet Neurol"},{"issue":"4","key":"10973_CR12","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001014","volume":"8","author":"F Graus","year":"2021","unstructured":"Graus F, Vogrig A, Mu\u00f1iz-Castrillo S et al (2021) Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm 8(4):e1014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"8","key":"10973_CR13","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1136\/jnnp.2003.034447","volume":"75","author":"F Graus","year":"2004","unstructured":"Graus F, Delattre JY, Antoine JC et al (2004) Recommended diagnostic criteria for paraneoplastic neurological syndromes. Neurol Neurosurg Psychiatry 75(8):1135\u20131140","journal-title":"Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10973_CR14","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.3389\/fimmu.2020.01482","volume":"14","author":"R Ruiz-Garc\u00eda","year":"2020","unstructured":"Ruiz-Garc\u00eda R, Mart\u00ednez-Hern\u00e1ndez E, Saiz A et al (2020) The diagnostic value of onconeural antibodies depends on how they are tested. Front Immunol 14(11):1482","journal-title":"Front Immunol"},{"issue":"1","key":"10973_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/ana.24979","volume":"82","author":"A Gadoth","year":"2017","unstructured":"Gadoth A, Pittock SJ, Dubey D et al (2017) Expanded phenotypes and outcomes among 256 LGI1\/CASPR2-IgG-positive patients. Ann Neurol 82(1):79\u201392","journal-title":"Ann Neurol"},{"issue":"11","key":"10973_CR16","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1001\/jamaneurol.2016.2549","volume":"73","author":"B Fang","year":"2016","unstructured":"Fang B, McKeon A, Hinson SR et al (2016) Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis. JAMA Neurol 73(11):1297\u20131307","journal-title":"JAMA Neurol"},{"issue":"11","key":"10973_CR17","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1177\/1352458519837705","volume":"25","author":"S Salama","year":"2019","unstructured":"Salama S, Khan M, Pardo S et al (2019) MOG antibody-associated encephalomyelitis\/encephalitis. Mult Scler 25(11):1427\u20132143","journal-title":"Mult Scler"},{"key":"10973_CR18","doi-asserted-by":"publisher","DOI":"10.1177\/20552173211022767)","author":"F Held","year":"2021","unstructured":"Held F, Kalluri SR, Berthele A et al (2021) Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients. Mult Scler J Exp Transl Clin. https:\/\/doi.org\/10.1177\/20552173211022767)","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"2","key":"10973_CR19","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000674","volume":"7","author":"M Reindl","year":"2020","unstructured":"Reindl M, Schanda K, Woodhall M et al (2020) International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflamm 7(2):e674","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-10973-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-10973-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-10973-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T04:32:05Z","timestamp":1655872325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-10973-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,25]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10973"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-10973-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,25]]},"assertion":[{"value":"12 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AG has a patent for MAP1B as the antigen for PCA-2-associated paraneoplastic syndrome and as a biomarker for SCLC which is diagnosed by IFA (1 patient in this study). YS, YP, OA, YA have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}